EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy

Jinjin Wang iD, Xisha Huang, Qiangqiang Shi iD, Kelsey L Swingle iD, Alex G Hamilton iD, Ningqiang Gong, Michael J Mitchell iD

Proceedings of the National Academy of Sciences · 11.11.2025 · 122 (45)

DOI: 10.1073/pnas.2409564122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.11.2025. Verfasst von Jinjin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: T-Lymphocytes, Antibodies, Bispecific, Immunotherapy, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific T cell engager (BiTE) therapeutics that link T cells and tumor cells to induce tumor cell lysis have demonstrated great success in the clinic for the treatment of many cancers. However, T cell exhaustion in the tumor microenvironment leads to tumor cell escape and BiTE therapy resistance. Herein, we developed a drug-loaded bispecific T cell nanoengager (NanoBiTE) to overcome this obstacle. NanoBiTE is composed of a mesoporous silica nanoparticle encapsulating the adenosine A2A receptor antagonist PBF-509 as a core, with a lipid layer surface coating as a shell and modification with anti-CD19 and anti-CD3 antibodies for tumor and T cell binding, respectively. Like the traditional BiTE blinatumomab, NanoBiTE can engage T cells with CD19 + tumor cells to promote tumor cell lysis. However, unlike blinatumomab, which tends to induce T cell exhaustion, we showed that the release of PBF-509 from NanoBiTE suppressed the A2AR pathway and substantially improved tumor cell killing induced by NanoBiTE. Moreover, NanoBiTE treatment led to substantially reduced tumor burden in vivo in a humanized mouse model. Our results demonstrate that NanoBiTE is a safe and potent bispecific therapy that can also reduce T cell exhaustion for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesAntibodies, BispecificImmunotherapyNanoparticlesNeoplasmsAnimalsMiceHumansCell Line, TumorTumor MicroenvironmentReceptor, Adenosine A2AFemaleT-Cell Exhaustion

Stichwörter der Autor:innen

T cellcancerimmunotherapynanomedicine

Substanzen

Antibodies, BispecificReceptor, Adenosine A2Ablinatumomab

Autor:innen und Institutionen

  • Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104.
  • Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Science and Medicine, University of Science and Technology of China, Hefei 230026, China.
  • Penn Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA 19104.
  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
  • Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
  • Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.

ORCID-Profile: Jinjin Wang, Qiangqiang Shi, Kelsey L Swingle, Alex G Hamilton, Michael J Mitchell

Zitieren

APA

Wang, J., Huang, X., Shi, Q., Swingle, K. L., Hamilton, A. G., Gong, N., & Mitchell, M. J. (2025). Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proceedings of the National Academy of Sciences, 122(45). https://doi.org/10.1073/pnas.2409564122

Vancouver

Wang J, Huang X, Shi Q, Swingle KL, Hamilton AG, Gong N, et al. Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proceedings of the National Academy of Sciences. 2025;122(45). doi:10.1073/pnas.2409564122

BibTeX
@article{Wang2025,
  author = {Wang, Jinjin and Huang, Xisha and Shi, Qiangqiang and Swingle, Kelsey L and Hamilton, Alex G and Gong, Ningqiang and Mitchell, Michael J},
  title = {Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {45},
  doi = {10.1073/pnas.2409564122}
}
Kostenlos starten →